June 30 Financial Quick Takes: $40M series B for Hinova; plus TriArm and PredictImmune raise rounds
Hinova Pharmaceuticals raises $40M series B
Hinova Pharmaceuticals Inc (Chengdu, China) completed a $40 million series B round led by Hermed Capital and Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196), with participation from Lang Sheng Investment, Prosper Capital, Silicon Valley Torch Fund, Dingjian New Material Partnership Ltd. Hinova's lead candidate, HC-1119, is in Phase III testing for prostate cancer.
Panacea, Virtus Inspire back T cell play TriArm in series A
Aiming to expand and develop its pipeline of T cell therapies for cancer, TriArm Therapeutics (Shanghai, China) raised $20 million in a series A round led by Panacea Venture and Virtus Inspire Ventures with participation by Efung Capital and Lombard Odier Co-Investment. The company says its non-viral gene transfer technology can reduce CAR T cell preparation times to 2-3 days. ...